FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 36 of 40
Feb 4, 2026Despite regulatory pressures from the FDA, Amgen maintains that Tavneos remains an effective treatment option for patients with rare diseases. This decision highlights the ongoing complexities in drug approval and regulatory enforcement, particularly regarding rare disease therapeutics.
Feb 4, 2026In a recent legislative development, the U.S. President signed a spending package into law that includes the reauthorization of the FDA's rare pediatric disease priority review voucher program, a key initiative incentivizing drug development for rare diseases affecting children. Additionally, the bill funds reforms targeted at pharmacy benefit managers (PBMs), marking a significant policy shift with potential wide-reaching implications for drug approval processes and the pharmaceutical supply chain.
Feb 3, 2026Recent news confirms measles infections at two Immigration and Customs Enforcement (ICE) detention facilities. This development highlights ongoing challenges in disease prevention and control within congregate settings, especially among immigrant detainees who may face barriers to healthcare access.
Feb 2, 2026The FDA's newly launched PreCheck program represents a strategic effort to streamline and enhance the regulatory oversight and support for pharmaceutical manufacturers. By facilitating more frequent interactions, the program aims to improve compliance, efficiency, and innovation in manufacturing processes.
Feb 2, 2026Pharmaceutical companies face growing pressure to openly disclose drug pricing decisions and rebate structures. This shift towards transparency is driven by calls for credibility and fairness in an industry historically opaque about costs, affecting stakeholder trust and regulatory scrutiny.
Feb 1, 2026Recent regulatory developments have put Regenxbio's gene therapy programs for rare diseases under significant scrutiny. This article examines the implications of FDA clinical holds, potential safety concerns, and the broader context of gene therapy regulation in rare disease treatment.
Jan 31, 2026Shared decision-making involves collaboration between clinicians and patients to make healthcare decisions that align with patient values and preferences. This approach fosters trust and improves treatment adherence, especially in nuanced areas such as prostate cancer screening and vaccine choices.
Jan 31, 2026The recent draft guidance from the U.S. Food and Drug Administration on multiple myeloma demonstrates significant progress in understanding this complex cancer. It takes into account advancements in diagnostic tools and altered patient care journeys shaped by better therapies, underscoring ongoing efforts to streamline clinical development and regulatory evaluation in this field.
Jan 30, 2026The Senate's inability to pass a comprehensive spending package has placed the rare pediatric disease priority review voucher program in limbo, as the bill also encompasses controversial funding for federal immigration enforcement. This regulatory challenge highlights the complexities of healthcare policy-making interwoven with broader political debates and raises questions about future support for rare disease initiatives.
Jan 30, 2026Health Secretary Robert F. Kennedy Jr. indicated in a recent Cabinet meeting that the TrumpRx website might go live within approximately ten days, yet clarity on the exact launch date remains elusive amid scrutiny over regulatory compliance.
Jan 30, 2026Summit Therapeutics is developing a novel immunotherapy intended to be used in combination with chemotherapy for locally advanced or metastatic non-squamous non-small cell lung cancer. The FDA’s review and upcoming decision are pivotal milestones in the drug's regulatory pathway.
Jan 30, 2026On January 29, 2026, the White House unveiled a fresh, ambitious effort to streamline the country’s approach to addiction. While the rhetoric marks a strong commitment to tackling drug and alcohol misuse, key specifics needed to evaluate the initiative’s potential impact remain unclear. This article explores the context, potential implications, and challenges of this new policy approach.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.